Novel agents in the management of castration resistant prostate cancer

@inproceedings{Chaturvedi2014NovelAI,
  title={Novel agents in the management of castration resistant prostate cancer},
  author={Shruti Chaturvedi and Jorge A. Garc{\'i}a},
  booktitle={Journal of carcinogenesis},
  year={2014}
}
Prostate cancer (PCa) is a leading cause of cancer mortality in men and despite high cure rates with surgery and/or radiation, 30-40% of patients will eventually develop advanced disease. Androgen deprivation is the first line therapy for standard of care for men with advanced disease. Eventually however all men will progress to castration-resistant prostate cancer (CRPC). Insight into the molecular mechanisms of androgen resistance has led to the development of alternative novel hormonal… CONTINUE READING